Cite
HARVARD Citation
Müller, V. et al. (2021). First-line bevacizumab-containing therapy for HER2-negative locally advanced/metastatic breast cancer: Real-world experience from >2000 patients treated in the multicentre AVANTI study. Breast. pp. 70-77. [Online].